Swiss pharmaceutical giant Novartis (NYSE: NVS) has presented compelling real-world data for its innovative small interfering RNA (siRNA) therapy, Leqvio (inclisiran), which is used for the treatment of atherosclerotic cardiovascular disease (ASCVD) in patients who have not responded well to statins. The data, unveiled last week, demonstrated that the early introduction of Leqvio to statin therapy resulted in a significant reduction of low-density lipoprotein cholesterol (LDL-C) levels in 70% of ASCVD patients. This is a stark contrast to the control group, which continued with the standard regimen and only saw a reduction in 7% of cases. The safety profile of Leqvio was found to be in line with previous long-term clinical observations.
Leqvio’s administration method also enhances treatment adherence in cholesterol management. It is given subcutaneously twice a year following two initial doses spaced three months apart. This convenience, along with its demonstrated efficacy, positions Leqvio as a promising therapy for ASCVD patients who are not adequately managed with statins alone. The drug is currently approved in over 90 markets worldwide, making it a widely accessible option for patients in need.- Flcube.com
